Novel Therapies in Gynecologic Cancer.
Am Soc Clin Oncol Educ Book
; 42: 1-17, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-35594502
ABSTRACT
During the past decade, considerable strides have been made in the understanding and treatment of gynecologic cancers. The advent of PARP inhibitors, antiangiogenic therapies, immunotherapy combinations, and targeted agents have altered the standard of care in ovarian, endometrial, and cervical cancers. However, continued advancement in the treatment of gynecologic cancers is critical. Fortunately, exciting work defining new therapeutic targets and novel treatment strategies is on the horizon. Here, we discuss emerging treatments for gynecologic cancers, including endometrial, cervical, ovarian, and rare gynecologic cancers. We highlight research that has deepened our understanding of the unique biology and molecular underpinnings of these cancers and is being translated into powerful new treatment approaches. We particularly highlight the advent of immunotherapy in endometrial cancer; radiosensitizers in cervical, vaginal, and vulvar cancers; targeted therapies in ovarian cancer; and molecularly driven approaches to treat rare gynecologic cancers. Continued basic, translational, and clinical research holds the promise to change the landscape of gynecologic cancer and improve the lives of all women impacted by these diseases.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Neoplasias del Cuello Uterino
/
Neoplasias Endometriales
/
Neoplasias de los Genitales Femeninos
Límite:
Female
/
Humans
Idioma:
En
Revista:
Am Soc Clin Oncol Educ Book
Año:
2022
Tipo del documento:
Article
País de afiliación:
España